LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Charles River Laboratories International Inc

Închisă

SectorSănătate

166.05 1.65

Rezumat

Modificarea prețului

24h

Curent

Minim

159.38

Maxim

168.72

Indicatori cheie

By Trading Economics

Venit

2.9M

56M

Vânzări

-27M

1B

EPS

2.43

Marjă de profit

5.529

Angajați

18,700

EBITDA

-23M

198M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+26.93% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-862M

7.9B

Deschiderea anterioară

164.4

Închiderea anterioară

166.05

Sentimentul știrilor

By Acuity

5%

95%

149 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 feb. 2026, 23:07 UTC

Câștiguri

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb. 2026, 23:01 UTC

Câștiguri

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb. 2026, 22:59 UTC

Câștiguri

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb. 2026, 22:42 UTC

Câștiguri

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb. 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb. 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb. 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb. 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb. 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb. 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 feb. 2026, 23:16 UTC

Câștiguri

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb. 2026, 23:13 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb. 2026, 23:12 UTC

Câștiguri

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb. 2026, 23:10 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb. 2026, 23:10 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb. 2026, 23:08 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb. 2026, 23:07 UTC

Câștiguri

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb. 2026, 22:52 UTC

Câștiguri

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb. 2026, 22:46 UTC

Câștiguri

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb. 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Warner Receives New Bid From Paramount -- 3rd Update

24 feb. 2026, 22:29 UTC

Câștiguri

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb. 2026, 22:28 UTC

Câștiguri

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb. 2026, 22:27 UTC

Câștiguri

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb. 2026, 22:27 UTC

Câștiguri

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb. 2026, 22:25 UTC

Câștiguri

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb. 2026, 22:24 UTC

Câștiguri

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb. 2026, 22:23 UTC

Câștiguri

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb. 2026, 22:22 UTC

Câștiguri

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb. 2026, 22:22 UTC

Câștiguri

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb. 2026, 22:21 UTC

Câștiguri

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

26.93% sus

Prognoză pe 12 luni

Medie 207.56 USD  26.93%

Maxim 265 USD

Minim 175 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

8

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

117.16 / 144.77Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

149 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat